{
    "clinical_study": {
        "@rank": "26773", 
        "arm_group": {
            "arm_group_label": "Secukinumab", 
            "arm_group_type": "Experimental", 
            "description": "All subjects will be assigned to receive secukinumab 150 mg. Secukinumab 150 mg s.c. injection will be administered at BSL, Weeks 1, 2, 3, 4. Prior to receiving the Week 8 dose, all subjects will be assigned to the following treatment group based on clinical components of their CGI evaluation at Week 8.\n\"No up-titration\" group will receive 1 injection of secukinumab 150 mg at Weeks 8, 12, and each visit from Week 16 until Week 48.\n\"Up-titration\" group will receive 2 injections of secukinumab 150 mg at Weeks 8, 9, 12 and each visit from Week 16 until Week 48.\nSubjects receiving secukinumab 150 mg can be up-titrated to secukinumab 300 mg at any visit starting at Week 16 based on clinical components of their CGI evaluation and investigator's discretion."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess efficacy and safety data of secukinumab in Japanese\n      subjects with generalized pustular psoriasis (GPP). This study is expected to support the\n      filing of secukinumab in the indication of pustular psoriasis in Japan."
        }, 
        "brief_title": "Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At baseline, presence of GPP classified on the basis of the criteria for diagnosis of\n             GPP by Japanese Dermatological Association (JDA)\n\n          -  At baseline, erythema area with pustule \u2265 10%\n\n        Exclusion Criteria:\n\n          -  Erythrodermic, guttate psoriasis, or subcorneal pustular dermatosis at screening.\n\n          -  At baseline, : total score of JDA severity index for GPP \u2265 14\n\n          -  Drug-induced psoriasis\n\n          -  Ongoing use of prohibited psoriasis treatments.\n\n        Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01952015", 
            "org_study_id": "CAIN457A1302"
        }, 
        "intervention": {
            "arm_group_label": "Secukinumab", 
            "description": "Secukinumab 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose)", 
            "intervention_name": "Secukinumab", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "generalized pustular psoriasis", 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Nagoya-city", 
                        "country": "Japan", 
                        "state": "Aichi", 
                        "zip": "467-8602"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-city", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "814-0180"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kitakyushu", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "800-0296"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Asahikawa-city", 
                        "country": "Japan", 
                        "state": "Hokkaido", 
                        "zip": "078-8510"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo-city", 
                        "country": "Japan", 
                        "state": "Hokkaido", 
                        "zip": "060-0063"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Inashiki-gun", 
                        "country": "Japan", 
                        "state": "Ibaraki", 
                        "zip": "300-0395"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Isehara-city", 
                        "country": "Japan", 
                        "state": "Kanagawa", 
                        "zip": "259-1193"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka-city", 
                        "country": "Japan", 
                        "state": "Osaka", 
                        "zip": "550-0012"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shimotsuke-city", 
                        "country": "Japan", 
                        "state": "Tochigi", 
                        "zip": "329-0498"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiyoda-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "102-8798"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hachioji", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "192-0032"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minato-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "105-8471"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinjuku-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "160-0023"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kofu-city", 
                        "country": "Japan", 
                        "state": "Yamanashi", 
                        "zip": "400-8506"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Terminated"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyoto", 
                        "country": "Japan", 
                        "zip": "606-8507"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-center, Open Label Study of Subcutaneous Secukinumab in Prefilled Syringes as Mono- or Co-therapy to Assess the Efficacy, Safety and Tolerability up to 52 Weeks in Japanese Subjects With Generalized Pustular Psoriasis", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+81337978748"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Treatment success is defined as \"Minimally improved\", \"Much improved\" or \"Very much improved\" in Clinical global impression (CGI)", 
            "measure": "Propotion of subjects who experience treatment success of secukinumab at Week 16", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01952015"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Clinically meaningful success is defined as follows: 1) For subjects who receive secukinumab as monotherapy: \"Minimally improved\", \"Much improved\" or \"Very much improved\" in CGI, 2) For subjects who receive secukimumab as co-medication together with other immunomodulatory drug: a. ONLY IF the co-medication is not meaningfully reduced: \"Minimally improved\", \"Much improved\" or \"Very much improved\" in CGI, b. ONLY IF the co-medication is meaningfully reduced: \"No-change\", \"Minimally improved\", \"Much improved\" or \"Very much improved\" in CGI.", 
                "measure": "Clinically meaningful success of secukinumab at week 16", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "Treatment success and the clinically meaningful success of secukinumab at Week 52", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "description": "CGI has five categories: Very much improved, Much improved, Minimally improved, No change and Wesened.", 
                "measure": "CGI", 
                "safety_issue": "No", 
                "time_frame": "evert 4 weeks"
            }, 
            {
                "description": "JDA severity index for GPP consists of area of etythema with pustules, area of erythema (total), area of edema, fever, WBC, hsCRP and serum albumin. The total score of JDA severity index for GPP is assigned a score of 0-17 (0=best, 17=worst).", 
                "measure": "Change from baseline in the total score and the category of the JDA severity index for GPP", 
                "safety_issue": "No", 
                "time_frame": "every 4 weeks"
            }, 
            {
                "description": "Area of erythema with pustules, area of erythema (total), area of edema are rated as 0 to 3. Fever, WBC, hsCRP and serum albumin are rated as 0 to 2.", 
                "measure": "Change from baseline in components of the JDA severity index for GPP", 
                "safety_issue": "No", 
                "time_frame": "every 4 weeks"
            }, 
            {
                "measure": "Change from baseline in observed value of components of the JDA severity index for GPP", 
                "safety_issue": "No", 
                "time_frame": "every 4 weeks"
            }, 
            {
                "description": "Clinical safety and tolerability of secukinumab as assessed by vital signs, clinical laboratory variables, ECGs, and adverse events monitoring.", 
                "measure": "Clinical safety and tolerability of secukinumab", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 60 weeks"
            }, 
            {
                "description": "The Short Form Health Survey (SF-36) ) is a widely used and extensively studied instrument to measure health-related quality of life among healthy subjects and patients with acute and chronic conditions. It consists of eight subscales that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health.", 
                "measure": "Change from baseline in SF-36", 
                "safety_issue": "No", 
                "time_frame": "every 4 weeks"
            }, 
            {
                "description": "The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability index designed to assess health-related quality of life in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts.", 
                "measure": "Change from baseline in DLQI", 
                "safety_issue": "No", 
                "time_frame": "every 4 weeks"
            }, 
            {
                "description": "Use of systemic co-medication to treat GPP, in subjects who have active GPP treatment at baseline.", 
                "measure": "Use of systemic co-medication to treat GPP", 
                "safety_issue": "No", 
                "time_frame": "every 4 weeks"
            }, 
            {
                "description": "Use of topical co-medication to treat GPP, in subjects who have active GPP treatment at baseline.", 
                "measure": "Use of topical co-medication to treat GPP", 
                "safety_issue": "No", 
                "time_frame": "every 4 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}